Ventus therapeutics announces first participant dosed in clinical study with an nlrp3 inhibitor licensed exclusively to novo nordisk

Waltham, mass. & montreal--(business wire)--ventus therapeutics, inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, resolve™, to develop differentiated small molecule therapeutics, today announced that its partner, novo nordisk, has successfully dosed the first participant in a phase 1 clinical study for nnc6022-0001 (formerly known as vent-01) – an oral nlrp3 inhibitor licensed by novo nordisk in september 2022. “.
NVO Ratings Summary
NVO Quant Ranking